Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML-CP)

NCT06423911 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT06423911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06423911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML-CP)
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
February 5, 2024
Completion date
July 10, 2028
Enrollment
333 (estimated)
Sites
163

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia, cml, cml, chronic phase